DelveInsight’s, “Advanced Endometrial Cancer Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Advanced Endometrial Cancer pipeline landscape. It covers the Advanced Endometrial Cancer pipeline drug profiles, including Advanced Endometrial Cancer clinical trials and nonclinical stage products. It also covers the Advanced Endometrial Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Endometrial Cancer Pipeline Report

 

• DelveInsight’s Advanced Endometrial Cancer Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Advanced Endometrial Cancer treatment.

 

• The leading Advanced Endometrial Cancer Companies include Incyte Corporation, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Genentech, NETRIS Pharma, Takeda, and Others

 

• Promising Advanced Endometrial Cancer Pipeline Therapies include Selinexor, Matching Placebo for selinexor, Lerociclib, Letrozole 2.5mg, Olaparib, Durvalumab, AEZS-108 / zoptarelin doxorubicin, pembrolizumab, carboplatin, paclitaxel, arzoxifene, and others

 

• The Advanced Endometrial Cancer companies and academics are working to assess challenges and seek opportunities that could influence Advanced Endometrial Cancer R&D. The Advanced Endometrial Cancer therapies under development are focused on novel approaches to treat/improve Advanced Endometrial Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Advanced Endometrial Cancer Pipeline landscape @ Advanced Endometrial Cancer Pipeline Outlook

 

Advanced Endometrial Cancer Overview

Metastatic or advanced uterine (endometrial) cancer is a type of cancer that originated in the lining of the uterus (endometrium) and has spread to distant areas of the body. In general, uterine cancer can metastasize to the rectum or bladder. Other areas where it may spread include the vagina, ovaries and fallopian tubes. This form of cancer is typically slow growing and often detected before it has spread to more distant areas of the body.

 

Advanced Endometrial Cancer Emerging Drugs

 

• Retifanlimab: Incyte Corporation

Retifanlimab (formerly INCMGA0012), an investigational intravenous PD-1 inhibitor, is currently under evaluation in registration-directed trials as a monotherapy for patients with microsatellite instability-high endometrial cancer, Merkel cell carcinoma and squamous cell carcinoma of the anal canal (SCAC); and in combination with platinum-based chemotherapy for patients with non-small cell lung cancer and SCAC.

 

• Trastuzumab duocarmazine (SYD985): Byondis

The most advanced compound in the company’s pipeline is trastuzumab duocarmazine (US non-proprietary name [vic-]trastuzumab duocarmazine). This investigational anti-HER2 ADC, targets a broad range of HER2-expressing cancers such as (metastatic) breast, gastric, bladder (urothelial) and uterine (endometrial) cancer. Trastuzumab duocarmazine could be used in patients where other (anti-HER2) treatments have failed, reflecting our philosophy of developing new, innovative medicines for relentless cancers. Trastuzumab duocarmazine is Byondis’ frontrunner ADC. The antibody, trastuzumab, can bind to a specific protein, HER2 (Human Epidermal growth factor Receptor 2) on the cell surface of tumor cells in many different tumor types. The linker-drug in trastuzumab duocarmazine is vc-seco-DUBA.

 

For further information, refer to the detailed Advanced Endometrial Cancer Drugs Launch, Advanced Endometrial Cancer Developmental Activities, and Advanced Endometrial Cancer News, click here for Advanced Endometrial Cancer Ongoing Clinical Trial Analysis

 

Advanced Endometrial Cancer Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Advanced Endometrial Cancer. The companies which have their Advanced Endometrial Cancer drug candidates in the most advanced stage, i.e. phase II include, Incyte Corporation.

 

Advanced Endometrial Cancer Pipeline Segmentation

 

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Advanced Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Find out more about the Advanced Endometrial Cancer Pipeline Segmentation, Therapeutics Assessment, and Advanced Endometrial Cancer Emerging Drugs @ Advanced Endometrial Cancer Treatment Landscape

 

Scope of the Advanced Endometrial Cancer Pipeline Report

 

• Coverage- Global

 

• Advanced Endometrial Cancer Companies- Incyte Corporation, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Genentech, NETRIS Pharma, Takeda, and Others

 

• Advanced Endometrial Cancer Pipeline Therapies- Selinexor, Matching Placebo for selinexor, Lerociclib, Letrozole 2.5mg, Olaparib, Durvalumab, AEZS-108 / zoptarelin doxorubicin, pembrolizumab, carboplatin, paclitaxel, arzoxifene, and others.

 

• Advanced Endometrial Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Advanced Endometrial Cancer Pipeline Companies and Therapies, click here @ Advanced Endometrial Cancer Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Endometrial Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Endometrial Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Selinexor: Karyopharm Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Retifanlimab: Incyte Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Alsevalimab: Five Prime Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Advanced Endometrial Cancer Key Companies
18. Advanced Endometrial Cancer Key Products
19. Advanced Endometrial Cancer- Unmet Needs
20. Advanced Endometrial Cancer- Market Drivers and Barriers
21. Advanced Endometrial Cancer- Future Perspectives and Conclusion
22. Advanced Endometrial Cancer Analyst Views
23. Advanced Endometrial Cancer Key Companies
24. Appendix

 

Got Queries? Find out the related information on Advanced Endometrial Cancer Mergers and acquisitions, Advanced Endometrial Cancer Licensing Activities @ Advanced Endometrial Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services